VIZZ Drug Patent Profile

When do Vizz patents expire, and what generic alternatives are available?

Vizz is a drug marketed by Lenz Therap and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and thirteen patent family members in twenty-four countries.

The generic ingredient in VIZZ is aceclidine hydrochloride. One supplier is listed for this compound. Additional details are available on the aceclidine hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Vizz

Vizz will be eligible for patent challenges on July 31, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 31, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VIZZ

International Patents:	113
US Patents:	6
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for VIZZ

VIZZ is protected by six US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lenz Therap	VIZZ	aceclidine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	218585-001	Jul 31, 2025		RX	Yes	Yes	12,533,347
Lenz Therap	VIZZ	aceclidine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	218585-001	Jul 31, 2025		RX	Yes	Yes
Lenz Therap	VIZZ	aceclidine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	218585-001	Jul 31, 2025		RX	Yes	Yes	12,128,036

International Patents for VIZZ

See the table below for patents covering VIZZ around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2014311558
Australia	2016280615
Australia	2016280616

Last updated: April 25, 2026

VIZZ (Drug) — What Do the Patents and Fundamentals Indicate for Investors?

What is VIZZ, and which assets drive the investment case?

No information is provided in the prompt identifying VIZZ as a specific drug product (active ingredient, dosage form, route, sponsor, or country), or identifying the patent family(ies) and legal status (grants, filings, expiries, or litigation). Without an identifiable reference product and jurisdiction, a fundamentals-and-patents investment analysis for “VIZZ” cannot be produced accurately.

What do the patent fundamentals say about duration, exclusivity, and risk?

None can be stated without the drug’s INN/brand linkage and patent data (publication numbers, assignee, jurisdictions, priority dates, expiration dates, SPC status, and any IPR challenges). A VIZZ investment analysis that claims patent strength, remaining term, or expiry-driven revenue risk would be fabricated without those inputs.

How strong are the commercialization fundamentals (sales trajectory, adoption, and pricing power)?

No market fundamentals are provided (current sales, growth, channel coverage, payer status, formulary placement, pricing history, or usage metrics). Without these, any claims on revenue durability, margin profile, or competitive positioning would be unsupported.

What is the competitive and regulatory landscape impact on valuation?

No geography, indication, mechanism class, competitors, label scope, trial readouts, or regulatory status are provided. Competitive intensity and label-driven revenue risk cannot be mapped without:

• the indication set and label language
• competing branded and generic products
• trial pipelines affecting substitution or clinical positioning
• regulatory milestones (approvals, refusals, withdrawals)

What are the actionable implications for investors?

No actionable investment conclusions can be issued for “VIZZ” in the absence of identifiable drug-level facts and patent/legal context.

---

Key Takeaways

• A VIZZ investment and fundamentals analysis cannot be completed without the underlying drug identity (active ingredient, indication, jurisdictional product mapping) and patent/legal data.
• Patent-duration, exclusivity risk, competitive pressure, and commercialization durability cannot be quantified from the prompt as written.

---

FAQs

1. What information is required to analyze VIZZ patents and exclusivity?
   Active ingredient, jurisdiction(s), patent family identifiers, priority/filing dates, grant status, expiry/SPC status, and legal events.

2. How do patent expiries typically change the investment outlook for branded drugs?
   They shape generic entry timing, settlement outcomes, and expected revenue step-down profiles.

3. What commercialization metrics matter most for drug fundamentals?
   Indication-level sales, growth rates, payer coverage, net pricing trends, and discontinuation or substitution signals.

4. How is competitive risk assessed in pharma investing?
   By mapping label overlap, efficacy/safety differentiation, access status, and expected substitution dynamics post-approval and post-expiry.

5. Can a branded drug be analyzed without an indication and label scope?
   No, indication and label language determine market size, uptake, payer behavior, and competitive set.

---

References

[1] None.